Search research articles
Contact Us
Filters
Showing results (1-10 of 83) with videos related to
Page
of 9
Sort By:
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
June 25, 2026
[SAKK 09/10: dose-intensified salvage radiotherapy for biochemical recurrence after prostatectomy-no benefit, but additional toxicity?]
Mohamed Shelan
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
June 24, 2025
[HYDRA meta-analysis: hypofractionated radiotherapy for prostate cancer-have we reached our goal?]
Mohamed Shelan
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
May 8, 2023
[Hyaluronic acid spacers for optimizing rectal dose in hypofractionated radiotherapy of the prostate]
Reinhardt Krcek, Mohamed Shelan
Translational Andrology and Urology
|
July 12, 2026
Baseline vulnerability over dosimetric precision: reframing late urinary toxicity after prostate stereotactic body radiotherapy
Mohamed Shelan, Banu Atalar, Federica Ferrario
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
June 22, 2022
[Multimodality treatment in high-risk and very high-risk prostate cancer: outcomes from international phase III randomized controlled trials]
Etienne Mathier, Astrid Heusel, Mohamed Shelan
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
July 23, 2021
[Virtual prostatectomy using single dose radiotherapy]
Mohamed Shelan, Elena Riggenbach, Daniel M Aebersold
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
February 21, 2025
[The EMBARK trial: The use of enzalutamide in biochemically recurrent prostate cancer after primary therapy]
Mohamed Shelan, Etienne Mathier, Daniel M Aebersold, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
June 30, 2021
[Single dose of 24 Gy or 3-fraction SBRT regimen in the treatment of oligometastatic cancer? : A phase III multi-center trial]
Hossein Hemmatazad, Etienne Mathier, Daniel M Aebersold, et al.
Head & Neck
|
October 12, 2018
Risk analysis for tracheostomy dependency in curatively treated laryngeal cancer with organ preservation
Lukas Anschuetz, Miranda Visini, Mohamed Shelan, et al.
The Laryngoscope
|
October 24, 2020
Predicting Factors for Oncological and Functional Outcome in Hypopharyngeal Cancer
Miranda Visini, Roland Giger, Mohamed Shelan, et al.
Page
of 9
Search research articles
Search
Showing results (1-10 of 83) with videos related to
Sort By:
Page
of 9
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
June 25, 2026
[SAKK 09/10: dose-intensified salvage radiotherapy for biochemical recurrence after prostatectomy-no benefit, but additional toxicity?]
Mohamed Shelan
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
June 24, 2025
[HYDRA meta-analysis: hypofractionated radiotherapy for prostate cancer-have we reached our goal?]
Mohamed Shelan
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
May 8, 2023
[Hyaluronic acid spacers for optimizing rectal dose in hypofractionated radiotherapy of the prostate]
Reinhardt Krcek, Mohamed Shelan
Translational Andrology and Urology
|
July 12, 2026
Baseline vulnerability over dosimetric precision: reframing late urinary toxicity after prostate stereotactic body radiotherapy
Mohamed Shelan, Banu Atalar, Federica Ferrario
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
June 22, 2022
[Multimodality treatment in high-risk and very high-risk prostate cancer: outcomes from international phase III randomized controlled trials]
Etienne Mathier, Astrid Heusel, Mohamed Shelan
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
July 23, 2021
[Virtual prostatectomy using single dose radiotherapy]
Mohamed Shelan, Elena Riggenbach, Daniel M Aebersold
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
February 21, 2025
[The EMBARK trial: The use of enzalutamide in biochemically recurrent prostate cancer after primary therapy]
Mohamed Shelan, Etienne Mathier, Daniel M Aebersold, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
June 30, 2021
[Single dose of 24 Gy or 3-fraction SBRT regimen in the treatment of oligometastatic cancer? : A phase III multi-center trial]
Hossein Hemmatazad, Etienne Mathier, Daniel M Aebersold, et al.
Head & Neck
|
October 12, 2018
Risk analysis for tracheostomy dependency in curatively treated laryngeal cancer with organ preservation
Lukas Anschuetz, Miranda Visini, Mohamed Shelan, et al.
The Laryngoscope
|
October 24, 2020
Predicting Factors for Oncological and Functional Outcome in Hypopharyngeal Cancer
Miranda Visini, Roland Giger, Mohamed Shelan, et al.
Page
of 9